

Fragilis Polyclonal Antibody
Purified Rabbit Polyclonal Antibody (Pab)
Catalog # AP54801**Specification****Fragilis Polyclonal Antibody - Product Information**

Application	WB, IHC-P, IHC-F, IF, ICC, E
Primary Accession	Q01628
Reactivity	Rat, Bovine
Host	Rabbit
Clonality	Polyclonal
Calculated MW	14632

Fragilis Polyclonal Antibody - Additional Information**Gene ID** 10410**Other Names**

Interferon-induced transmembrane protein 3, Dispanin subfamily A member 2b, DSPA2b, Interferon-inducible protein 1-8U, IFITM3

Dilution

**WB~~1:1000<br \>IHC-P~~N/A<br \>IHC-F~~N/A<br \>IF~~1:50~200<br \>ICC~~N/A<br \>E~~N/A</p>
</div>
<div data-bbox=**

[33239446](http://www.uniprot.org/citations/33239446), PubMed: [33270927](http://www.uniprot.org/citations/33270927)). Can inhibit: influenza virus hemagglutinin protein- mediated viral entry, MARV and EBOV GP1,2-mediated viral entry, SARS- CoV and SARS-CoV-2 S protein-mediated viral entry and VSV G protein- mediated viral entry (PubMed: [33270927](http://www.uniprot.org/citations/33270927)). Plays a critical role in the structural stability and function of vacuolar ATPase (v-ATPase). Establishes physical contact with the v-ATPase of endosomes which is critical for proper clathrin localization and is also required for the function of the v-ATPase to lower the pH in phagocytic endosomes thus establishing an antiviral state. In hepatocytes, IFITM proteins act in a coordinated manner to restrict HCV infection by targeting the endocytosed HCV virion for lysosomal degradation (PubMed: [26354436](http://www.uniprot.org/citations/26354436)). IFITM2 and IFITM3 display anti-HCV activity that may complement the anti-HCV activity of IFITM1 by inhibiting the late stages of HCV entry, possibly in a coordinated manner by trapping the virion in the endosomal pathway and targeting it for degradation at the lysosome (PubMed: [26354436](http://www.uniprot.org/citations/26354436)). Exerts opposing activities on SARS-CoV-2, including amphipathicity-dependent restriction of virus at endosomes and amphipathicity-independent enhancement of infection at the plasma membrane (PubMed: [33270927](http://www.uniprot.org/citations/33270927)).

Cellular Location


Cell membrane; Single-pass type II membrane protein. Late endosome membrane; Single-pass type II membrane protein. Early endosome membrane; Single-pass type II membrane protein. Lysosome membrane; Single-pass type II membrane protein. Cytoplasm, perinuclear region. Note=Co-localizes with BRI3 isoform 1 at the perinuclear region.


Fragilis Polyclonal Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)


Fragilis Polyclonal Antibody - Images





Blank control: U-2OS(blue)

Isotype Control Antibody: Rabbit IgG(orange) ; Secondary Antibody: Goat anti-rabbit IgG-PE(white blue), Dilution: 1:100 in 1 X PBS containing 0.5% BSA ; Primary Antibody Dilution: 1 μ l in 100 μ l 1X PBS containing 0.5% BSA(green).



Sample:

Spleen (Mouse) Lysate at 40 μ g

Primary: Anti-Fragilis (bs-12256R) at 1/300 dilution

Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution

Predicted band size: 40 kD

Observed band size: 40 kD